Kyoto University

Riken Corporation

National Institute of Radiological Sciences

Kaneka Corporation

National Institutes for Quantum and Radiological Science and Technology

Haruhisa Inoue

Takayuki Kondo

Ryosuke Takahashi

Keiko Imamura

Tetsuya Suhara

Hiroki Takeuchi

Makoto Higuchi

Koh Ono

Yuichiro Yada

Shiho Kitaoka

Bin Ji

Norio Nakatsuji

Motonari Uesugi

Kazuya Hamada

Tomohisa Kato

Takaomi Saido

Shigehiko Suzuki

Nobuhisa Iwata

Kazuhiro Aiba

Takahiro Horie

Shigeyoshi Itohara

Gaku Murakami

Fumiko Nakazeki

Takuji Iwasato

Kosuke Matsuzono

Motoko Naitoh

Naoki Yahata

Yuji Amagai

Yasuyuki Asai

Itaru Tsuge

Kayoko Tsukita

Kondo Takayuki

Naohiro Egawa

Masashi Asai

Ayako Asai

An information processing device includes: an acquirer configured to acquire images obtained by imaging cells differentiated from pluripotent stem cells derived from a subject; and a predictor configured to input the images acquired by the acquirer to a model trained on data in which information indicating at least a neurodegenerative disease is associated with the image obtained by imaging the cells of the neurodegenerative disease differentiated from the pluripotent stem cells, and predict an onset of the neurodegenerative disease of the subject or effects of drugs on the neurodegenerative disease, based on output results of the model to which the images were input.

Information processing device, screening device, information processing method, screening method, and program

An information processing device includes: an acquirer configured to acquire images obtained by imaging cells differentiated from pluripotent stem cells derived from a subject; and a predictor configured to input the images acquired by the acquirer to a model trained on data in which information indicating at least an intractable neurological disease is associated with an image obtained by imaging the cells of the intractable neurological disease differentiated from the pluripotent stem cells, and predict an onset of the intractable neurological disease of the subject based on output results of the model to which the images were input.

An object of the present invention is to provide a therapeutic agent for hereditary spastic paraplegia (HSP) SPG4. Specifically, the present invention relates to a composition for preventing or treating a neurodegenerative disease such as hereditary spastic paraplegia SPG4, the composition comprising, as an active ingredient, a substance that inhibits a function of miR-33a.

Composition for preventing or treating neurodegenerative disease

The present invention provides a prophylactic and/or therapeutic agent for Alzheimer's disease containing a compound represented by the formula (I) or the formula (II) or a salt thereof. Each symbol in the formulas (I) and (II) are as described in the attached DESCRIPTION: 

Agent for preventing and/or treating alzheimer's disease

An object of the present invention is to provide ASO that can effectively suppress a formation of RNA foci spontaneously occurring in neurons having SCA36 mutation, without inducing the cleavage of NOP56 pre-mRNA. The present invention provides an oligonucleotide comprising a nucleotide sequence in which one or more nucleotide sequences represented by SEQ ID NO: 2 are consecutively connected and is complementary to pre-mRNA of NOP56 gene, wherein a structure formed by the hybridization of the oligonucleotide to the pre-mRNA is resistant to RNaseH.

Composition for prevention or treatment of spinocerebellar ataxia type 36

The present invention provides a prophylactic or therapeutic agent for Alzheimer's disease (AD) containing a combination of two or more compounds selected from the group consisting of compounds shown by compound Nos. 1 to 130. Since these compounds are existing drugs that have already been confirmed actually for safety and pharmacokinetics in human, they can be a means for a pre-emptive treatment of people at risk of AD and in a stage before developing mild cognitive impairment (MCI).

Agent for preventing and/or treating Alzheimer's disease

A liquid injection method for injecting a liquid into a culture vessel includes tilting the culture vessel around a horizontal axis at a tilt angle (X&#xb0;) of greater than 0&#xb0; and 50&#xb0; or less, wherein adherent cells are adhered to the culture vessel; and injecting the liquid into the culture vessel at a predetermined linear velocity (Y mm/s) via a wall surface of the culture vessel tilted at the tilt angle (X&#xb0;), wherein the tilt angle (X) and the linear velocity (Y) satisfy the following (formula 1): Y&#x2264;5.075X+123 (formula 1).

Liquid injection method

The present invention aims to provide a composition for the prevention or treatment of TDP-43 proteinopathy using a microRNA targeting the TDP-43 gene. A prophylactic or therapeutic composition for TDP-43 proteinopathy, comprising: one or more nucleic adds selected from the group consisting of isolated RNAs and isolated nucleic acids encoding the RNAs, wherein the RNAs consist of human miR-33 represented by SEQ ID NO: 1, variants of the human miR-33 having one or more mutations, and precursors of the human miR-33 and the variants.

Therapeutic or prophylactic composition for TDP-43 proteinopathy

The present invention aims to provide a method of producing motor neurons/neurons that sufficiently reproduce intrinsic properties of motor neurons/neurons, especially of the motor neurons/neurons in patients, from pluripotent stem cells promptly and synchronically, and a pluripotent stem cell capable of differentiating into a neuron or a motor neuron promptly and synchronically after a drug treatment. A method of generating a motor neuron from a pluripotent stem cell, comprising the following steps in order from (1) to (2): (1) introducing one or more nucleic acids encoding Lhx3, Ngn2, and Isl1 into a pluripotent stem cell; and (2) maintaining expression of the Lhx3, Ngn2, and Isl1 for three days or more.

Induction of motor neurons from pluripotent stem cells

The present invention provides a prophylactic or therapeutic agent for amyotrophic lateral sclerosis, containing a 1,3-diphenylurea derivative or multikinase inhibitor.

Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis

The present invention provides a method for producing astrocytes from neural progenitor cells, the method comprising: (1) culturing neural progenitor cells in a culture medium comprising a neurotrophic factor; (2) dissociating the cells obtained in the step (1); and (3) subjecting the cells obtained in the step (2) to adherent culture in a culture medium comprising a neurotrophic factor using an uncoated culture vessel.

Method for inducing astrocytes

This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phospholylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.

Vaccine for treatment of tautopathy

The present invention provides a method for detecting onset of, or the risk of development of, a protein misfolding disease, and a method for predicting the age of onset of a protein misfolding disease using nerve cells derived from iPS cells. The present invention also provides a kit to be used in these methods.

Method for diagnosing a protein misfolding disease using nerve cells derived from iPS cells

This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.

It is intended to provide an agent for regulating axon extension during neuranagenesis by regulating ephrin-Eph receptor signaling mechanisms and to provide a mouse having abnormal ephrin-Eph receptor signaling mechanisms. The present invention relates to a regulator of axon extension, comprising an agent for promoting or suppressing the function of &#x3b1;-chimerin, and to a miffy (mfy) mouse derived from a B6 strain, which displays autosomal recessive inheritance of an abnormal walking trait exhibiting a hopping gait with left-right synchronized movement of limbs and has mutation in an &#x3b1;-chimerin gene.

Growing community of inventors

Kyoto, Japan

Haruhisa Inoue